Aptevo Therapeutics - Stock Price History | APVO

Historical daily share price chart and data for Aptevo Therapeutics since 2022 adjusted for splits. The latest closing stock price for Aptevo Therapeutics as of September 23, 2022 is 3.12.
  • The all-time high Aptevo Therapeutics stock closing price was 112.00 on July 20, 2016.
  • The Aptevo Therapeutics 52-week high stock price is 22.08, which is 607.7% above the current share price.
  • The Aptevo Therapeutics 52-week low stock price is 3.03, which is 2.9% below the current share price.
  • The average Aptevo Therapeutics stock price for the last 52 weeks is 6.72.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Aptevo Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 22.2459 37.1800 40.5900 6.4800 7.8700 -78.53%
2020 12.0493 8.9992 48.3600 3.1100 36.6500 299.98%
2019 12.4830 19.8800 26.1800 7.3640 9.1630 -48.46%
2018 56.7587 66.5000 83.1600 17.3600 17.7800 -70.05%
2017 31.6894 35.0000 59.6400 16.6600 59.3600 73.77%
2016 37.6965 112.0000 112.0000 25.6200 34.1600 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.016B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00